CSIMarket


Cell Source Inc   (CLCS)
Other Ticker:  
 


 

Cell Source Inc

CLCS's Financial Statements and Analysis



Cell Source Inc increased second quarter of 2023 net loss per share of $-0.04 compare to net loss per share of $-0.04 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.05 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -0.04 $  0 Mill
Unch.     Unch.    



Cell Source Inc 's Revenue fell by 0 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by sequentially.


Cell Source Inc is Expected to report next financial results on August 06, 2024.

More on CLCS's Income Statement



Cell Source Inc 's in thesecond quarter of 2023 recorded net loss of $-1.242 million, an improvement compare to net loss of $-1.286 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-1.692 million realized in previous quarter.

More on CLCS's Growth

Cell Source Inc Inventories
In Jun 30 2023 company's net cash and cash equivalents decreased by $0 million


Cell Source Inc does not pay out common stock dividend.

In trailing twelve-month period Cell Source Inc payed $ -0.08 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.40 per share from $ -0.38.

Company issued 0.15 million shares or 0.41 % in Jun 30 2023.


More on CLCS's Dividends

 Market Capitalization (Millions) 11
 Shares Outstanding (Millions) 37
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Cell Source Inc does not pay out common stock dividend.

In trailing twelve-month period Cell Source Inc had negative $ -0.08 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -0.40 per share from $ -0.38.

Company issued 0.15 million shares or 0.41 % in Jun 30 2023.


More on CLCS's Balance Sheets

 Market Capitalization (Millions) 11
 Shares Outstanding (Millions) 37
 Total Debt (Millions $) 1
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Cell Source Inc Earnings

Cell Source Inc Delights Shareholders with Substantial Gain and Promising Operating Deficit Reduction in Q2 of 2023 Earnings Season

Investors Remain Watchful as Cell Source Inc Maneuvers Operating Deficit During Recent Earnings Season
In the latest earnings season that spanned from April to June 30, 2023, Cell Source Inc, the renowned Major Pharmaceutical Preparations company, experienced a lack of significant improvements in its top-line performance. However, investors closely monitored the company's operating deficit, which stood at $-0.905465 million during this period. This figure, although representing a deficit, overshadowed the corresponding timeframe in the previous fiscal year ending June 30, 2022. Given Cell Source Inc's focus on research and development activities, this outcome was largely anticipated.
Throughout the s...


Date modified: 2023-10-05T21:43:08+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com